Early Cancer Detection Stocks
Next-generation molecular diagnostics and screening platforms leverage genomic sequencing, liquid biopsies, and biological markers to identify malignancies at asymptomatic stages where curative intervention is most viable.
As of Oct 23, 2026, Early Cancer Detection has 21 US-listed companies worth $105B combined. The median member moved -2.1% over the past week; GRAL led at +12.5% and BIAF trailed at -24.9%.
Companies in Early Cancer Detection
- NTRA – Natera Inc, $57.9B
- GH – Guardant Health Inc, $21.9B
- CAI – Caris Life Sciences, Inc. Common Stock, $9B
- GRAL – GRAIL, LLC, $5.7B
- VCYT – Veracyte Inc, $3.7B
- NEO – NeoGenomics Inc, $2.1B
- PSNL – Personalis Inc, $1.7B
- FRNM – Freenome, Inc. Common stock, $1.4B
- YDES – YD Bio Ltd, $477M
- PRE – Prenetics Global Ltd, $361M
- BNR – Burning Rock Biotech Ltd, $158M
- LUCD – Lucid Diagnostics Inc, $116M
- ANIX – Anixa Biosciences Inc, $101M
- PAVM – PAVmed Inc, $18.3M
- ADVB – Advanced Biomed Inc. Common Stock, $10.5M
- VNRX – Volitionrx Ltd, $5.4M
- BIAF – bioAffinity Technologies, Inc., $4.8M
- BGLC – BioNexus Gene Lab Corp Common stock, $3.6M
- AIDX – 20/20 Biolabs, Inc. Common Stock, $3.3M
- ONCO – Onconetix Inc, $2.5M
- PRPH – ProPhase Labs Inc, $155,925